StreetInsider.com News Articles

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios^® (abemaciclib) in mainland China:

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

Tue, 30 Jun 2026 00:00:00 -0400

Innovent will be responsible for the importation, marketing, distribution

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin Biosciences has completed a $330 million Series B financing round to fund global Phase 3 trials of OLN324, a VEGF/Ang2 bispecific antibody being developed for diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), according to a statement from partner Innovent Biologics (HKEX: 01801).

The round was co-led by TCGX and ARCH Venture Partners, with participation from a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board, RA Capital Management, accounts advised by T. Rowe Price Investment Management, and an unnamed sovereign wealth fund. Existing investors Mubadala Capital and Monograph Capital also participated.

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the

Ollin Biosciences raises $330M Series B to fund eye disease trials

Wed, 24 Jun 2026 20:00:21 -0400

Ollin plans to initiate the